Leif E Sander

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2622784/publications.pdf

Version: 2024-02-01

95 papers	12,085 citations	53794 45 h-index	42399 92 g-index
123 all docs	123 docs citations	123 times ranked	22239 citing authors

#	Article	IF	Citations
1	Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. Nature Biotechnology, 2022, 40, 319-324.	17.5	229
2	Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months. Respiratory Medicine, 2022, 191, 106709.	2.9	63
3	Altered fibrin clot structure and dysregulated fibrinolysis contribute toÂthrombosis risk in severe COVID-19. Blood Advances, 2022, 6, 1074-1087.	5.2	35
4	A proteomic survival predictor for COVID-19 patients in intensive care. , 2022, 1, e0000007.		28
5	mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nature Medicine, 2022, 28, 477-480.	30.7	342
6	Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. Cell Host and Microbe, 2022, 30, 69-82.e10.	11.0	42
7	A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae. Vaccine, 2022, 40, 1038-1046.	3.8	2
8	Cutting Edge: Serum but Not Mucosal Antibody Responses Are Associated with Pre-Existing SARS-CoV-2 Spike Cross-Reactive CD4+ T Cells following BNT162b2 Vaccination in the Elderly. Journal of Immunology, 2022, 208, 1001-1005.	0.8	16
9	Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell, 2022, 185, 493-512.e25.	28.9	122
10	Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults. Lancet Infectious Diseases, The, 2022, 22, 445-446.	9.1	28
11	Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections. Emerging Infectious Diseases, 2022, 28, 1050-1052.	4.3	11
12	Characterization of antimicrobial use and co-infections among hospitalized patients with COVID-19: a prospective observational cohort study. Infection, 2022, 50, 1441-1452.	4.7	10
13	Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies. Journal of Clinical Immunology, 2022, 42, 1111-1129.	3.8	17
14	A multiplex protein panel assay for severity prediction and outcome prognosis in patients with COVID-19: An observational multi-cohort study. EClinicalMedicine, 2022, 49, 101495.	7.1	17
15	SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 960-971.	1.9	20
16	A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting. Journal of Infectious Diseases, 2021, 223, 10-14.	4.0	21
17	Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. Nature Biotechnology, 2021, 39, 705-716.	17.5	129
18	Breakdown in membrane asymmetry regulation leads to monocyte recognition of P. falciparum-infected red blood cells. PLoS Pathogens, 2021, 17, e1009259.	4.7	14

#	Article	IF	Citations
19	Clonal expansion of CD4+CD8+ T cells in an adult patient with Mycoplasma pneumoniae-associated Erythema multiforme majus. Allergy, Asthma and Clinical Immunology, 2021, 17, 17.	2.0	2
20	SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients. Frontiers in Immunology, 2021, 12, 629185.	4.8	42
21	Ultra-fast proteomics with Scanning SWATH. Nature Biotechnology, 2021, 39, 846-854.	17.5	173
22	Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study. Infection, 2021, 49, 703-714.	4.7	27
23	CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity. Infection, 2021, 49, 757-762.	4.7	47
24	Swarm Learning for decentralized and confidential clinical machine learning. Nature, 2021, 594, 265-270.	27.8	375
25	Estimating infectiousness throughout SARS-CoV-2 infection course. Science, 2021, 373, .	12.6	389
26	Echocardiographic Evaluation of Right Ventricular (RV) Performance over Time in COVID-19-Associated ARDSâ€"A Prospective Observational Study. Journal of Clinical Medicine, 2021, 10, 1944.	2.4	0
27	Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. Frontiers in Immunology, 2021, 12, 690698.	4.8	52
28	Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study. Clinical Microbiology and Infection, 2021, 27, 1520.e7-1520.e10.	6.0	13
29	Heart failure with preserved ejection fraction according to the HFAâ€PEFF score in COVID â€19 patients: clinical correlates and echocardiographic findings. European Journal of Heart Failure, 2021, 23, 1891-1902.	7.1	21
30	Cross-reactive CD4 ⁺ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. Science, 2021, 374, eabh1823.	12.6	221
31	Temporal omics analysis in Syrian hamsters unravel cellular effector responses to moderate COVID-19. Nature Communications, 2021, 12, 4869.	12.8	68
32	A time-resolved proteomic and prognostic map of COVID-19. Cell Systems, 2021, 12, 780-794.e7.	6.2	125
33	Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, Februaryâ€"March 2021. Emerging Infectious Diseases, 2021, 27, 2169-2173.	4.3	17
34	Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respiratory Medicine,the, 2021, 9, 1255-1265.	10.7	279
35	Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany. Emerging Infectious Diseases, 2021, 27, 2174-2178.	4.3	67
36	Early IFN-Î± signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity, 2021, 54, 2650-2669.e14.	14.3	145

#	Article	IF	Citations
37	Follicular Helperâ€“like T Cells in the Lung Highlight a Novel Role of B Cells in Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1403-1417.	5.6	16
38	Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. EClinicalMedicine, 2021, 40, 101099.	7.1	52
39	Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers. Lancet Respiratory Medicine,the, 2021, 9, e104-e105.	10.7	65
40	Untimely TGFÎ² responses in COVID-19 limit antiviral functions of NK cells. Nature, 2021, 600, 295-301.	27.8	146
41	Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccinesâ€”A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters. Viruses, 2021, 13, 2290.	3.3	7
42	SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell, 2021, 184, 6243-6261.e27.	28.9	277
43	RNA-Cholesterol Nanoparticles Function as Potent Immune Activators via TLR7 and TLR8. Frontiers in Immunology, 2021, 12, 658895.	4.8	7
44	Macrophage activation syndrome in a patient with adult-onset Stillâ€™s disease following first COVID-19 vaccination with BNT162b2. BMC Rheumatology, 2021, 5, 60.	1.6	13
45	A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. Cell, 2020, 183, 1058-1069.e19.	28.9	305
46	Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19. Immunity, 2020, 53, 1296-1314.e9.	14.3	278
47	Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. Cell, 2020, 182, 1419-1440.e23.	28.9	1,162
48	Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection. Cell Systems, 2020, 11, 11-24.e4.	6.2	439
49	Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19). Infection, 2020, 48, 619-626.	4.7	79
50	Phage capsid nanoparticles with defined ligand arrangement block influenza virus entry. Nature Nanotechnology, 2020, 15, 373-379.	31.5	96
51	Noncoding RNA MalL1 is an integral component of the TLR4â€“TRIF pathway. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9042-9053.	7.1	33
52	COVID-19 severity correlates with airway epitheliumâ€“immune cell interactions identified by single-cell analysis. Nature Biotechnology, 2020, 38, 970-979.	17.5	887
53	Toward a universal flu vaccine. Science, 2020, 367, 852-853.	12.6	10
54	Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. Frontiers in Immunology, 2020, 11, 628971.	4.8	51

#	Article	IF	Citations
55	SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature, 2020, 587, 270-274.	27.8	1,115
56	Abstract 14962: Empagliflozinâ€™s Cardiovascular Impact in High-Risk Patients With Type 2 Diabetes and Obstructive Pulmonary Disease: An Inquiry From EMPA-REG OUTCOME. Circulation, 2020, 142, .	1.6	0
57	Innate sensors that regulate vaccine responses. Current Opinion in Immunology, 2019, 59, 31-41.	5.5	21
58	Myeloid cells require gp130 signaling for protective antiâ€inflammatory functions during sepsis. FASEB Journal, 2019, 33, 6035-6044.	0.5	13
59	Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida albicans. Cell, 2019, 176, 1340-1355.e15.	28.9	321
60	Dead or alive: how the immune system detects microbial viability. Current Opinion in Immunology, 2019, 56, 60-66.	5.5	26
61	The cGAS/STING Pathway Detects Streptococcus pneumoniae but Appears Dispensable for Antipneumococcal Defense in Mice and Humans. Infection and Immunity, 2018, 86, .	2.2	18
62	Recognition of microbial viability via TLR8 drives TFH cell differentiation and vaccine responses. Nature Immunology, 2018, 19, 386-396.	14.5	139
63	Sensing Microbial Viability through Bacterial RNA Augments T Follicular Helper Cell and Antibody Responses. Immunity, 2018, 48, 584-598.e5.	14.3	71
64	The mitochondrial respiratory chain: A metabolic rheostat of innate immune cell-mediated antibacterial responses. Mitochondrion, 2018, 41, 28-36.	3.4	30
65	Local Encounters: Extrafollicular T-Cell/B-Cell Interactions in Airway Inflammation. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 403-404.	2.9	0
66	Antibiotic treatmentâ€“induced secondary IgA deficiency enhances susceptibility to Pseudomonas aeruginosa pneumonia. Journal of Clinical Investigation, 2018, 128, 3535-3545.	8.2	75
67	The common HAQ STING variant impairs cGAS-dependent antibacterial responses and is associated with susceptibility to Legionnairesâ€™ disease in humans. PLoS Pathogens, 2018, 14, e1006829.	4.7	43
68	Lymphocyte Circadian Clocks Control Lymph Node Trafficking and Adaptive Immune Responses. Immunity, 2017, 46, 120-132.	14.3	324
69	Spectrum of pathogen- and model-specific histopathologies in mouse models of acute pneumonia. PLoS ONE, 2017, 12, e0188251.	2.5	64
70	IFNs Modify the Proteome of Legionella-Containing Vacuoles and Restrict Infection Via IRG1-Derived Itaconic Acid. PLoS Pathogens, 2016, 12, e1005408.	4.7	195
71	Mucosal BCG Vaccination Induces Protective Lung-Resident Memory T Cell Populations against Tuberculosis. MBio, 2016, 7, .	4.1	205
72	NLRP3 protects alveolar barrier integrity by an inflammasome-independent increase of epithelial cell adherence. Scientific Reports, 2016, 6, 30943.	3.3	20

#	Article	IF	Citations
73	A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection. Cell Chemical Biology, 2016, 23, 1407-1416.	5.2	51
74	Mitochondrial respiratory-chain adaptations in macrophages contribute to antibacterial host defense. Nature Immunology, 2016, 17, 1037-1045.	14.5	259
75	Interferon-Î³ regulates growth and controls FcÎ³ receptor expression and activation in human intestinal mast cells. BMC Immunology, 2014, 15, 27.	2.2	21
76	Adjuvant immunotherapies as a novel approach to bacterial infections. Immunotherapy, 2013, 5, 365-381.	2.0	13
77	Retinol-Binding Protein 4 and Its Membrane Receptor STRA6 Control Adipogenesis by Regulating Cellular Retinoid Homeostasis and Retinoic Acid Receptor Î± Activity. Molecular and Cellular Biology, 2013, 33, 4068-4082.	2.3	77
78	NOD-Like Receptors in Lung Diseases. Frontiers in Immunology, 2013, 4, 393.	4.8	57
79	NLRC4 inflammasomes in dendritic cells regulate noncognate effector function by memory CD8+ T cells. Nature Immunology, 2012, 13, 162-169.	14.5	150
80	Improved vaccines through targeted manipulation of the body's immunological riskâ€assessment?. BioEssays, 2012, 34, 876-884.	2.5	3
81	Beyond pattern recognition: five immune checkpoints for scaling the microbial threat. Nature Reviews Immunology, 2012, 12, 215-225.	22.7	229
82	Differential Role of gp130-Dependent STAT and Ras Signalling for Haematopoiesis Following Bone-Marrow Transplantation. PLoS ONE, 2012, 7, e39728.	2.5	3
83	Detection of prokaryotic mRNA signifies microbial viability and promotes immunity. Nature, 2011, 474, 385-389.	27.8	378
84	Lack of interleukin-6/glycoprotein 130/signal transducers and activators of transcription-3 signaling in hepatocytes predisposes to liver steatosis and injury in mice. Hepatology, 2010, 51, 463-473.	7.3	71
85	Prothymosin-Î± inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10178-10183.	7.1	83
86	Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. Journal of Experimental Medicine, 2010, 207, 1453-1464.	8.5	295
87	Hepatocyte-specific NEMO deletion promotes NK/NKT cellâ€“ and TRAIL-dependent liver damage. Journal of Experimental Medicine, 2009, 206, 1727-1737.	8.5	83
88	Innate Immune Cells Cast an Eye on DNA. Journal of Molecular Cell Biology, 2009, 1, 77-79.	3.3	3
89	Inflammasome and toll-like receptor 9: Partners in crime in toxic liver injury. Hepatology, 2009, 49, 2119-2121.	7.3	3
90	Vesicle associated membrane protein (VAMP)â€7 and VAMPâ€8, but not VAMPâ€2 or VAMPâ€3, are required for activationâ€induced degranulation of mature human mast cells. European Journal of Immunology, 2008, 38, 855-863.	2.9	97

#	Article	IF	Citations
91	Hepatocyte-specific inhibitor-of-kappaB-kinase deletion triggers the innate immune response and promotes earlier cell proliferation during liver regeneration. Hepatology, 2008, 47, 2036-2050.	7.3	50
92	Gp130 Signaling Promotes Development of Acute Experimental Colitis by Facilitating Early Neutrophil/Macrophage Recruitment and Activation. Journal of Immunology, 2008, 181, 3586-3594.	0.8	37
93	Lessons from a patient with an unusual hepatic overlap syndrome. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 635-640.	1.7	3
94	Is interleukin-6 a gender-specific risk factor for liver cancer?. Hepatology, 2007, 46, 1304-1305.	7.3	24
95	Selective expression of histamine receptors H1R, H2R, and H4R, but not H3R, in the human intestinal tract. Gut, 2006, 55, 498-504.	12.1	133